Topical Drug Delivery Market by Product (Formulation (Semi-solid, Emulsion), Transdermal Patch, Microneedle Patch, Drug-in-adhesive, Matrix Patch), Application (Dermal, Ophthalmic, Nasal, Vaginal, Rectal), End User, Region - Global Forecast to 2030

1 INTRODUCTION 36 1.1 STUDY OBJECTIVES 36 1.2 MARKET DEFINITION 36 1.2.1 INCLUSIONS & EXCLUSIONS 36 1.2.2 MARKETS & REGIONS COVERED 37 1.2.3 YEARS CONSIDERED 38 1.2.4 CURRENCY CONSIDERED 38 1.3 MARKET STAKEHOLDERS 39 1.4 LIMITATIONS 39 1.5 SUMMARY OF CHANGES 39 2 RESEARCH METHODOLOGY 41 2.1 RESEARCH DATA 41 2.2 RESEARCH METHODOLOGY DESIGN 41 2.2.1 SECONDARY DATA 42 2.2.1.1 Key data from secondary sources 43 2.2.2 PRIMARY DATA 43 2.2.2.1 Key data from primary sources 45 2.2.2.2 Key industry insights 45 2.3 MARKET SIZE ESTIMATION 47 2.3.1 APPROACH 1: REVENUE SHARE ANALYSIS 47 2.3.2 APPROACH 2: PHARMACEUTICAL SALES ANALYSIS 49 2.3.3 APPROACH 3: TOP-DOWN APPROACH 50 2.3.4 APPROACH 4: BOTTOM-UP APPROACH 50 2.3.5 APPROACH 4: PRIMARY INTERVIEWS 51 2.3.6 APPROACH 5: DEMAND-SIDE APPROACH 51 2.3.7 APPROACH 6: VOLUME DATA ANALYSIS 52 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 55 2.5 MARKET SHARE ANALYSIS 56 2.6 STUDY ASSUMPTIONS 56 2.6.1 GROWTH RATE ASSUMPTIONS 56 2.7 RISK ASSESSMENT 57 2.8 LIMITATIONS 57 2.8.1 METHODOLOGY-RELATED LIMITATIONS 57 2.8.2 SCOPE-RELATED LIMITATIONS 57 3 EXECUTIVE SUMMARY 58   4 PREMIUM INSIGHTS 61 4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW 61 4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT & COUNTRY (2024) 62 4.3 TOPICAL DRUG DELIVERY MARKET: REGIONAL MIX 63 4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63 4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 64 5 MARKET OVERVIEW 65 5.1 INTRODUCTION 65 5.2 MARKET DYNAMICS 66 5.2.1 DRIVERS 66 5.2.1.1 Increasing prevalence of skin disorders 66 5.2.1.2 High incidence of burn injuries 67 5.2.1.3 Growing emphasis on patient convenience 68 5.2.1.4 Increasing investments in pharmaceutical R&D 69 5.2.1.5 Rising incidence of chronic diseases 70 5.2.2 RESTRAINTS 71 5.2.2.1 Adverse skin reactions & allergies 71 5.2.2.2 Drug failure & recalls of TDD systems 71 5.2.2.3 High development costs of topical drug delivery products 72 5.2.3 OPPORTUNITIES 73 5.2.3.1 Growing preference for self-administration and home care 73 5.2.3.2 High growth potential of emerging economies 73 5.2.4 CHALLENGES 74 5.2.4.1 Technical barriers related to skin irritation & permeability 74 5.3 INDUSTRY TRENDS 75 5.3.1 ADVANCES IN TRANSDERMAL DRUG DELIVERY SYSTEMS 75 5.3.2 EMERGENCE OF MICRONEEDLE PATCH TECHNOLOGIES 76 5.4 TECHNOLOGY ANALYSIS 77 5.4.1 KEY TECHNOLOGIES 77 5.4.1.1 Nanocarrier-based delivery systems 77 5.4.1.2 Microemulsions & nanoemulsion 77 5.4.1.3 Thermosensitive & pH-sensitive hydrogels & hydrocolloids 78 5.4.2 COMPLEMENTARY TECHNOLOGIES 79 5.4.2.1 Microneedle-enhanced delivery 79 5.4.2.2 AI-assisted formulations & prediction models 79 5.4.3 ADJACENT TECHNOLOGIES 80 5.4.3.1 Wearable sensor-integrated topical patches 80 5.4.3.2 3D testing skin models 80   5.5 PORTER’S FIVE FORCES ANALYSIS 81 5.5.1 THREAT OF NEW ENTRANTS 82 5.5.2 THREAT OF SUBSTITUTES 83 5.5.3 BARGAINING POWER OF SUPPLIERS 83 5.5.4 BARGAINING POWER OF BUYERS 83 5.5.5 INTENSITY OF COMPETITIVE RIVALRY 83 5.6 REGULATORY LANDSCAPE 84 5.6.1 REGULATORY ANALYSIS 84 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 5.7 PATENT ANALYSIS 88 5.7.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY 88 5.7.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS 89 5.8 TRADE ANALYSIS 90 5.8.1 TRADE DATA FOR HS CODE 300490 90 5.8.1.1 Import data for HS Code 300490 90 5.8.1.2 Export data for HS Code 300490 91 5.9 PRICING ANALYSIS 91 5.9.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022−2024 92 5.9.2 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024 93 5.9.3 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024 93 5.9.4 AVERAGE SELLING PRICE, BY REGION 94 5.9.5 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024 94 5.9.5.1 Average selling price trend of ointments, by region, 2022−2024 95 5.9.5.2 Average selling price trend of creams, by region, 2022−2024 95 5.9.5.3 Average selling price trend of gels, by region, 2022−2024 95 5.10 REIMBURSEMENT ANALYSIS 95 5.11 KEY CONFERENCES & EVENTS, 2025–2026 97 5.12 KEY STAKEHOLDERS & BUYING CRITERIA 99 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 99 5.12.2 BUYING CRITERIA 99 5.13 UNMET NEEDS/END-USER EXPECTATIONS 101 5.14 IMPACT OF AI ON TOPICAL DRUG DELIVERY MARKET 102 5.14.1 AI-USE CASES 103 5.15 PIPELINE ANALYSIS 103 5.16 ECOSYSTEM MARKET MAP 105 5.17 VALUE CHAIN ANALYSIS 106 5.18 INVESTMENT & FUNDING SCENARIO 108   5.19 TRUMP TARIFF IMPACT ON TOPICAL DRUG DELIVERY MARKET 109 5.19.1 INTRODUCTION 109 5.19.2 KEY TARIFF RATES 110 5.19.3 PRICE IMPACT ANALYSIS 111 5.19.4 KEY IMPACT ON VARIOUS REGIONS 111 5.19.5 END-USE INDUSTRY IMPACT 113 6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT 115 6.1 INTRODUCTION 116 6.2 SEMI-SOLID FORMULATIONS 117 6.2.1 OINTMENTS 121 6.2.1.1 Wide applications in analgesic indications to drive market 121 6.2.2 CREAMS 124 6.2.2.1 High absorption capabilities to boost demand 124 6.2.3 LOTIONS 127 6.2.3.1 Convenient application to fuel uptake 127 6.2.4 GELS 129 6.2.4.1 Enhanced patient compliance and aesthetic appeal to drive market 129 6.2.5 PASTES 132 6.2.5.1 Prevention of skin irritation to fuel uptake 132 6.3 LIQUID FORMULATIONS 133 6.3.1 SUSPENSIONS 136 6.3.1.1 Higher rate of bioavailability and controlled onset of action to drive market 136 6.3.2 EMULSIONS 138 6.3.2.1 Versatile carriers for enhanced drug delivery to fuel uptake 138 6.3.3 SOLUTIONS 140 6.3.3.1 Uniform & rapid drug delivery to boost demand 140 6.4 SOLID FORMULATIONS 142 6.4.1 POWDERS 144 6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel market 144 6.4.2 SUPPOSITORIES 146 6.4.2.1 Ability to ensure drug compatibility to fuel market 146 6.4.3 FILM 148 6.4.3.1 Next-generation advancements to boost demand 148 6.5 TRANSDERMAL PRODUCTS 150 6.5.1 TRANSDERMAL PATCHES 152 6.5.1.1 Drug-in-adhesive patches 156 6.5.1.1.1 Enhanced drug release to fuel uptake 156 6.5.1.2 Matrix patches 157 6.5.1.2.1 Rising technological advancements to boost demand 157   6.5.1.3 Reservoir membrane patches 159 6.5.1.3.1 Prolonged drug delivery to fuel market 159 6.5.1.4 Microneedle patches 161 6.5.1.4.1 Ability to deliver APIs to support market growth 161 6.5.1.5 Iontophoresis patches 162 6.5.1.5.1 Low molecular weight patches to support market growth 162 6.5.1.6 Vapor patches 164 6.5.1.6.1 Ability to release essential oils to support market growth 164 6.5.2 TRANSDERMAL GELS 166 6.5.2.1 Rapid release of drugs to fuel uptake 166 6.5.3 TRANSDERMAL SPRAYS 168 6.5.3.1 Targeted approach to boost demand 168 6.6 OTHER PRODUCTS 169 7 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION 172 7.1 INTRODUCTION 173 7.2 DERMAL DRUG DELIVERY 173 7.2.1 STANDARD MEDIUM WITH HIGH DRUG ABSORPTION TO PROPEL MARKET 173 7.3 OPHTHALMIC DRUG DELIVERY 176 7.3.1 FOCUS ON MICROEMULSION-BASED FORMULATIONS TO BOOST DEMAND 176 7.4 VAGINAL DRUG DELIVERY 179 7.4.1 LIMITED INTERVENTION BY MEDICAL PERSONNEL TO DRIVE MARKET 179 7.5 RECTAL DRUG DELIVERY 181 7.5.1 COMBINATION OF LOCAL & SYSTEMIC THERAPY OF DRUGS TO FUEL UPTAKE 181 7.6 NASAL DRUG DELIVERY 182 7.6.1 QUICK ONSET OF DRUG ACTION & CONVENIENCE TO SUPPORT MARKET UPTAKE 182 8 TOPICAL DRUG DELIVERY MARKET, BY END USER 185 8.1 INTRODUCTION 186 8.2 HOME CARE SETTINGS 186 8.2.1 HIGH PREFERENCE, AFFORDABILITY, AND CONVENIENCE TO PROPEL MARKET 186 8.3 HOSPITALS & CLINICS 189 8.3.1 ADOPTION OF TOPICAL ANAESTHETICS FOR MEDICAL & SURGICAL SUB-SPECIALTIES TO DRIVE MARKET 189 8.4 AMBULATORY SURGERY CENTERS 191 8.4.1 UTILIZATION OF ANTIMICROBIAL TOPICAL DRUGS FOR TRAUMA CASES TO BOOST DEMAND 191 8.5 BURN CARE CENTERS 193 8.5.1 HIGH INCIDENCE OF BURN INJURIES AND UPTAKE OF OINTMENTS TO SUPPORT MARKET GROWTH 193 8.6 OTHER END USERS 194 9 TOPICAL DRUG DELIVERY MARKET, BY REGION 196 9.1 INTRODUCTION 197 9.2 NORTH AMERICA 198 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 199 9.2.2 US 203 9.2.2.1 Rising prevalence of skin diseases to drive market 203 9.2.3 CANADA 207 9.2.3.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth 207 9.3 EUROPE 211 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 212 9.3.2 GERMANY 216 9.3.2.1 Growing focus of R&D for pharmaceutical API development to boost demand 216 9.3.3 UK 220 9.3.3.1 Rising demand for painless treatment alternatives to fuel market 220 9.3.4 FRANCE 224 9.3.4.1 Rising incidence of diabetes and subsequent increase in skin lesions to drive market 224 9.3.5 ITALY 228 9.3.5.1 Rising demand for transdermal patches to propel market 228 9.3.6 SPAIN 232 9.3.6.1 Expanding research hub to fuel market 232 9.3.7 NETHERLANDS 236 9.3.7.1 Public awareness initiatives for preventive care to fuel uptake 236 9.3.8 REST OF EUROPE 240 9.4 ASIA PACIFIC 244 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 245 9.4.2 CHINA 250 9.4.2.1 Rising cases of communicable diseases to drive market 250 9.4.3 JAPAN 254 9.4.3.1 Increasing number of product approvals to drive market 254 9.4.4 INDIA 258 9.4.4.1 Growing focus on adoption of non-invasive drug delivery methods to drive market 258 9.4.5 AUSTRALIA 262 9.4.5.1 Increasing number of smokers to fuel uptake 262 9.4.6 SOUTH KOREA 266 9.4.6.1 Favorable government focus on expanding clinical trials to boost demand 266 9.4.7 THAILAND 270 9.4.7.1 Regulatory reforms and supportive healthcare initiatives to support market growth 270 9.4.8 VIETNAM 274 9.4.8.1 Increasing investments and regulatory reforms to fuel uptake 274 9.4.9 REST OF ASIA PACIFIC 278 9.5 LATIN AMERICA 282 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 282 9.5.2 BRAZIL 286 9.5.2.1 High prevalence of diabetes to propel market growth 286 9.5.3 MEXICO 290 9.5.3.1 Increasing prevalence of glaucoma to drive market 290 9.5.4 REST OF LATIN AMERICA 294 9.6 MIDDLE EAST & AFRICA 298 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 299 9.6.2 GCC COUNTRIES 302 9.6.2.1 Kingdom of Saudi Arabia (KSA) 306 9.6.2.1.1 Expanding healthcare infrastructure to boost demand 306 9.6.2.2 United Arab Emirates (UAE) 310 9.6.2.2.1 Increasing prevalence of diabetes to fuel uptake 310 9.6.2.3 Other GCC Countries 314 9.6.3 REST OF MIDDLE EAST & AFRICA 318 10 COMPETITIVE LANDSCAPE 323 10.1 OVERVIEW 323 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 323 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET 324 10.3 REVENUE ANALYSIS, 2020–2024 326 10.4 MARKET SHARE ANALYSIS 326 10.4.1 RANKING OF KEY MARKET PLAYERS 329 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 329 10.5.1 STARS 329 10.5.2 EMERGING LEADERS 330 10.5.3 PERVASIVE PLAYERS 330 10.5.4 PARTICIPANTS 330 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 331 10.5.5.1 Company footprint 331 10.5.5.2 Region footprint 332 10.5.5.3 Product footprint 333 10.5.5.4 Site of application footprint 334   10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 335 10.6.1 PROGRESSIVE COMPANIES 335 10.6.2 RESPONSIVE COMPANIES 335 10.6.3 DYNAMIC COMPANIES 335 10.6.4 STARTING BLOCKS 335 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 337 10.6.5.1 Detailed list of key startups/SME players 337 10.6.5.2 Competitive benchmarking of key emerging players/startups 337 10.7 BRAND/PRODUCT COMPARISON 338 10.7.1 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 338 10.8 R&D EXPENDITURE OF KEY PLAYERS 339 10.8.1 R&D EXPENDITURE OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET 339 10.9 COMPANY VALUATION & FINANCIAL METRICS 339 10.9.1 FINANCIAL METRICS 339 10.9.2 COMPANY VALUATION 340 10.10 COMPETITIVE SCENARIO 340 10.10.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS 340 10.10.2 DEALS 341 10.10.3 EXPANSIONS 342 10.10.4 OTHER DEVELOPMENTS 344 11 COMPANY PROFILES 345 11.1 KEY PLAYERS 345 11.1.1 JOHNSON & JOHNSON SERVICES, INC. 345 11.1.1.1 Business overview 345 11.1.1.2 Products offered 346 11.1.1.3 Recent developments 347 11.1.1.3.1 Product approvals 347 11.1.1.3.2 Deals 348 11.1.1.4 MnM view 348 11.1.1.4.1 Key strengths 348 11.1.1.4.2 Strategic choices 348 11.1.1.4.3 Weaknesses & competitive threats 348 11.1.2 GALDERMA 349 11.1.2.1 Business overview 349 11.1.2.2 Products offered 350 11.1.2.3 Recent developments 351 11.1.2.3.1 Product launches & approvals 351 11.1.2.3.2 Deals 352 11.1.2.3.3 Expansions 352   11.1.2.4 MnM view 353 11.1.2.4.1 Key strengths 353 11.1.2.4.2 Strategic choices 353 11.1.2.4.3 Weaknesses & competitive threats 353 11.1.3 BAYER AG 354 11.1.3.1 Business overview 354 11.1.3.2 Products offered 355 11.1.3.3 Recent developments 356 11.1.3.3.1 Product launches & approvals 356 11.1.3.3.2 Deals 356 11.1.3.4 MnM view 357 11.1.3.4.1 Key strengths 357 11.1.3.4.2 Strategic choices 357 11.1.3.4.3 Weaknesses & competitive threats 357 11.1.4 NOVARTIS AG 358 11.1.4.1 Business overview 358 11.1.4.2 Products offered 359 11.1.4.3 Recent developments 360 11.1.4.3.1 Deals 360 11.1.4.3.2 Other developments 360 11.1.4.4 MnM view 361 11.1.4.4.1 Key strengths 361 11.1.4.4.2 Strategic choices 361 11.1.4.4.3 Weaknesses & competitive threats 361 11.1.5 ABBVIE INC. 362 11.1.5.1 Business overview 362 11.1.5.2 Products offered 363 11.1.5.3 Recent developments 364 11.1.5.3.1 Product launches 364 11.1.5.3.2 Expansions 365 11.1.5.3.3 Other developments 365 11.1.5.4 MnM view 365 11.1.5.4.1 Key strengths 365 11.1.5.4.2 Strategic choices 366 11.1.5.4.3 Weaknesses & competitive threats 366 11.1.6 GLENMARK PHARMACEUTICALS LIMITED 367 11.1.6.1 Business overview 367 11.1.6.2 Products offered 368 11.1.6.3 Recent developments 370 11.1.6.3.1 Product approvals 370 11.1.6.3.2 Deals 373   11.1.7 GSK PLC. 374 11.1.7.1 Business overview 374 11.1.7.2 Products offered 375 11.1.7.3 Recent developments 376 11.1.7.3.1 Deals 376 11.1.7.3.2 Other developments 377 11.1.8 BAUSCH HEALTH COMPANIES INC. 378 11.1.8.1 Business overview 378 11.1.8.2 Products offered 379 11.1.8.3 Recent developments 381 11.1.8.3.1 Product launches & approvals 381 11.1.8.3.2 Deals 382 11.1.9 HISAMITSU PHARMACEUTICAL CO., INC. 383 11.1.9.1 Business overview 383 11.1.9.2 Products offered 384 11.1.9.3 Recent developments 385 11.1.9.3.1 Product launches, enhancements, and approvals 385 11.1.9.3.2 Deals 386 11.1.9.3.3 Expansions 386 11.1.10 CIPLA 387 11.1.10.1 Business overview 387 11.1.10.2 Products offered 388 11.1.10.3 Recent developments 391 11.1.10.3.1 Deals 391 11.1.11 VIATRIS INC. 392 11.1.11.1 Business overview 392 11.1.11.2 Products offered 393 11.1.11.3 Recent developments 395 11.1.11.3.1 Product launches & approvals 395 11.1.11.3.2 Deals 396 11.1.11.3.3 Other developments 396 11.1.12 ORGANON GROUP OF COMPANIES 397 11.1.12.1 Business overview 397 11.1.12.2 Products offered 398 11.1.12.3 Recent developments 399 11.1.12.3.1 Product approvals 399 11.1.12.3.2 Deals 399 11.1.13 PFIZER, INC. 400 11.1.13.1 Business overview 400 11.1.13.2 Products offered 401 11.1.13.3 Recent developments 402 11.1.13.3.1 Product approvals 402 11.1.13.3.2 Deals 402 11.1.14 CRESCITA THERAPEUTICS INC. 403 11.1.14.1 Business overview 403 11.1.14.2 Products offered 404 11.1.14.3 Recent developments 405 11.1.14.3.1 Deals 405 11.1.14.3.2 Other developments 405 11.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 406 11.1.15.1 Business overview 406 11.1.15.2 Products offered 407 11.1.15.3 Recent developments 408 11.1.15.3.1 Deals 408 11.1.15.3.2 Expansions 408 11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. 409 11.1.16.1 Business overview 409 11.1.16.2 Products offered 410 11.1.16.3 Recent developments 411 11.1.16.3.1 Deals 411 11.1.17 SOLVENTUM 412 11.1.17.1 Business overview 412 11.1.17.2 Products offered 413 11.1.17.3 Recent developments 414 11.1.17.3.1 Deals 414 11.1.18 LUYE PHARMA GROUP 415 11.1.18.1 Business overview 415 11.1.18.2 Products offered 416 11.1.18.3 Recent developments 417 11.1.18.3.1 Product approvals 417 11.1.18.3.2 Deals 417 11.1.19 LEAD CHEMICAL CO., LTD. 418 11.1.19.1 Business overview 418 11.1.19.2 Products offered 418 11.1.20 PURDUE PHARMA L.P. 419 11.1.20.1 Business overview 419 11.1.20.2 Products offered 419 11.1.21 LAVIPHARM 420 11.1.21.1 Business overview 420 11.1.21.2 Products offered 421   11.2 OTHER PLAYERS 422 11.2.1 CMP PHARMA, INC. 422 11.2.2 ENCORE DERMATOLOGY, INC. 423 11.2.3 RUSAN PHARMA LTD. 424 11.2.4 ADHEXPHARMA 425 12 APPENDIX 426 12.1 DISCUSSION GUIDE 426 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 431 12.3 RELATED REPORTS 433 12.4 AUTHOR DETAILS 434

TABLE 1 STANDARD CURRENCY CONVERSION RATES (USD) 38 TABLE 2 TOPICAL DRUG DELIVERY MARKET: RISK ASSESSMENT ANALYSIS 57 TABLE 3 KEY DEVELOPMENTS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS 76 TABLE 4 TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 82 TABLE 5 REGULATORY ADHERENCE FOR TOPICAL DRUG DELIVERY PRODUCTS, BY REGION 84 TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 9 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 10 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 11 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 12 TOPICAL DRUG DELIVERY MARKET: MAJOR PATENTS 89 TABLE 13 IMPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021–2024 (USD THOUSANDS) 90 TABLE 14 EXPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021–2024 (USD THOUSANDS) 91 TABLE 15 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2022–2024 92 TABLE 16 AVERAGE SELLING PRICE TREND OF OINTMENTS, BY REGION, 2022–2024 95 TABLE 17 AVERAGE SELLING PRICE TREND FOR CREAMS, BY REGION, 2022–2024 95 TABLE 18 AVERAGE SELLING PRICE TREND OF GELS, BY REGION, 2022–2024 95 TABLE 19 TOPICAL DRUG DELIVERY MARKET: KEY CONFERENCES & EVENTS, 2025–2026 97 TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS (%) 99 TABLE 21 KEY BUYING CRITERIA, BY END USER 100 TABLE 22 TOPICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE (2024) 104 TABLE 23 TOPICAL DRUG DELIVERY PRODUCTS PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM 105 TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 110 TABLE 25 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR TOPICAL DRUG DELIVERY PRODUCTS 110 TABLE 26 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS 111 TABLE 27 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS 112 TABLE 28 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS 113 TABLE 29 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS 113 TABLE 30 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 117 TABLE 31 KEY PLAYERS OFFERING SEMI-SOLID FORMULATIONS 118 TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 119 TABLE 33 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 120 TABLE 34 KEY PLAYERS OFFERING OINTMENTS 121 TABLE 35 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY REGION, 2023–2030 (TEN THOUSAND UNITS) 122 TABLE 36 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2023–2030 (USD BILLION) 123 TABLE 37 KEY PLAYERS OFFERING CREAMS 124 TABLE 38 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY REGION, 2023–2030 (TEN THOUSAND UNITS) 125 TABLE 39 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2023–2030 (USD BILLION) 126 TABLE 40 KEY PLAYERS OFFERING LOTIONS 127 TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2023–2030 (USD BILLION) 128 TABLE 42 KEY PLAYERS OFFERING GELS 129 TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY REGION, 2023–2030 (TEN THOUSAND UNITS) 130 TABLE 44 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2023–2030 (USD BILLION) 131 TABLE 45 KEY PLAYERS OFFERING PASTES 132 TABLE 46 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY REGION, 2023–2030 (TEN THOUSAND UNITS) 132 TABLE 47 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2023–2030 (USD BILLION) 133 TABLE 48 KEY PLAYERS OFFERING LIQUID FORMULATIONS 134 TABLE 49 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 134 TABLE 50 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 135 TABLE 51 KEY PLAYERS OFFERING SUSPENSIONS 136 TABLE 52 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2023–2030 (USD BILLION) 137 TABLE 53 KEY PLAYERS OFFERING EMULSIONS 138 TABLE 54 TOPICAL DRUG DELIVERY MARKET FOR EMULSIONS, BY COUNTRY, 2023–2030 (USD BILLION) 139 TABLE 55 KEY PLAYERS OFFERING SOLUTIONS 140 TABLE 56 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2023–2030 (USD BILLION) 141 TABLE 57 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 142 TABLE 58 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 143 TABLE 59 KEY PLAYERS OFFERING SOLID FORMULATIONS 144 TABLE 60 KEY PLAYERS OFFERING POWDERS 144 TABLE 61 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2023–2030 (USD BILLION) 145 TABLE 62 KEY PLAYERS OFFERING SUPPOSITORIES 146 TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2023–2030 (USD BILLION) 147 TABLE 64 KEY PLAYERS OFFERING FILM 148 TABLE 65 TOPICAL DRUG DELIVERY MARKET FOR FILM, BY COUNTRY, 2023–2030 (USD BILLION) 149 TABLE 66 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 150 TABLE 67 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2023–2030 (USD BILLION) 151 TABLE 68 KEY PLAYERS OFFERING TRANSDERMAL PRODUCTS 152 TABLE 69 KEY PLAYERS OFFERING TRANSDERMAL PATCHES 153 TABLE 70 TRANSDERMAL PATCHES MARKET, BY TYPE, 2023–2030 (USD BILLION) 153 TABLE 71 TRANSDERMAL PATCHES MARKET, BY REGION, 2023–2030 (TEN THOUSAND UNITS) 154 TABLE 72 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 155 TABLE 73 KEY PLAYERS OFFERING DRUG-IN-ADHESIVE PATCHES 156 TABLE 74 TRANSDERMAL DRUG-IN-ADHESIVE PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 157 TABLE 75 KEY PLAYERS OFFERING MATRIX PATCHES 158 TABLE 76 TRANSDERMAL MATRIX PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 158 TABLE 77 KEY PLAYERS OFFERING RESERVOIR MEMBRANE PATCHES 159 TABLE 78 TRANSDERMAL RESERVOIR MEMBRANE PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 160 TABLE 79 KEY PLAYERS OFFERING MICRONEEDLE PATCHES 161 TABLE 80 TRANSDERMAL MICRONEEDLE PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 162 TABLE 81 KEY PLAYERS OFFERING IONTOPHORESIS PATCHES 163 TABLE 82 TRANSDERMAL IONTOPHORESIS PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 163 TABLE 83 KEY PLAYERS OFFERING VAPOR PATCHES 164 TABLE 84 TRANSDERMAL VAPOR PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 165 TABLE 85 KEY PLAYERS OFFERING TRANSDERMAL GELS 166 TABLE 86 TRANSDERMAL GELS MARKET, BY REGION, 2023–2030 (TEN THOUSAND UNITS) 166 TABLE 87 TRANSDERMAL GELS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 167 TABLE 88 KEY PLAYERS OFFERING TRANSDERMAL SPRAYS 168 TABLE 89 TRANSDERMAL SPRAYS MARKET, BY REGION, 2023–2030 (TEN THOUSAND UNITS) 168 TABLE 90 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 169 TABLE 91 TOPICAL DRUG DELIVERY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD BILLION) 170 TABLE 92 KEY PLAYERS OFFERING OTHER PRODUCTS 171 TABLE 93 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 173 TABLE 94 KEY PLAYERS OFFERING DERMAL DRUG DELIVERY PRODUCTS 174 TABLE 95 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 175 TABLE 96 KEY PLAYERS OFFERING OPHTHALMIC DRUG DELIVERY PRODUCTS 177 TABLE 97 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 178 TABLE 98 KEY PLAYERS OFFERING VAGINAL DRUG DELIVERY PRODUCTS 179 TABLE 99 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 180 TABLE 100 KEY PLAYERS OFFERING RECTAL DRUG DELIVERY PRODUCTS 181 TABLE 101 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 182 TABLE 102 KEY PLAYERS OFFERING NASAL DRUG DELIVERY PRODUCTS 183 TABLE 103 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 184 TABLE 104 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 186 TABLE 105 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION) 188 TABLE 106 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD BILLION) 190 TABLE 107 TOPICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD BILLION) 192 TABLE 108 TOPICAL DRUG DELIVERY MARKET FOR BURN CARE CENTERS, BY COUNTRY, 2023–2030 (USD BILLION) 194 TABLE 109 TOPICAL DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 195 TABLE 110 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION) 198 TABLE 111 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 200 TABLE 112 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 201 TABLE 113 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 201 TABLE 114 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 201 TABLE 115 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 202 TABLE 116 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 202 TABLE 117 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 202 TABLE 118 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 203 TABLE 119 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 203 TABLE 120 US: KEY MACROINDICATORS 204 TABLE 121 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 205 TABLE 122 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 205 TABLE 123 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 205 TABLE 124 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 206 TABLE 125 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 206 TABLE 126 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 206 TABLE 127 US: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 207 TABLE 128 US: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 207 TABLE 129 CANADA: KEY MACROINDICATORS 208 TABLE 130 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 208 TABLE 131 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 209 TABLE 132 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 209 TABLE 133 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 209 TABLE 134 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 210 TABLE 135 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 210 TABLE 136 CANADA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 211 TABLE 137 CANADA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 211 TABLE 138 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 213 TABLE 139 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 213 TABLE 140 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 214 TABLE 141 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 214 TABLE 142 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 214 TABLE 143 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 215 TABLE 144 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 215 TABLE 145 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 216 TABLE 146 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 216 TABLE 147 GERMANY: KEY MACROINDICATORS 217 TABLE 148 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 218 TABLE 149 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 218 TABLE 150 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 218 TABLE 151 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 219 TABLE 152 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 219 TABLE 153 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 219 TABLE 154 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 220 TABLE 155 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 220 TABLE 156 UK: KEY MACROINDICATORS 221 TABLE 157 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 221 TABLE 158 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 222 TABLE 159 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 222 TABLE 160 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 222 TABLE 161 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 223 TABLE 162 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 223 TABLE 163 UK: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 224 TABLE 164 UK: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 224 TABLE 165 FRANCE: KEY MACROINDICATORS 225 TABLE 166 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 225 TABLE 167 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 226 TABLE 168 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 226 TABLE 169 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 226 TABLE 170 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 227 TABLE 171 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 227 TABLE 172 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 228 TABLE 173 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 228 TABLE 174 ITALY: KEY MACROINDICATORS 229 TABLE 175 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 229 TABLE 176 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 230 TABLE 177 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 230 TABLE 178 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 230 TABLE 179 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 231 TABLE 180 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 231 TABLE 181 ITALY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 232 TABLE 182 ITALY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 232 TABLE 183 SPAIN: KEY MACROINDICATORS 233 TABLE 184 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 233 TABLE 185 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 234 TABLE 186 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 234 TABLE 187 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 234 TABLE 188 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 235 TABLE 189 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 235 TABLE 190 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 236 TABLE 191 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 236 TABLE 192 NETHERLANDS: KEY MACROINDICATORS 237 TABLE 193 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 237 TABLE 194 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 238 TABLE 195 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 238 TABLE 196 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 238 TABLE 197 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 239 TABLE 198 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 239 TABLE 199 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 240 TABLE 200 NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 240 TABLE 201 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 241 TABLE 202 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 241 TABLE 203 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 242 TABLE 204 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 242 TABLE 205 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 242 TABLE 206 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 243 TABLE 207 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 243 TABLE 208 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 244 TABLE 209 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 247 TABLE 210 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 247 TABLE 211 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 248 TABLE 212 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 248 TABLE 213 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 248 TABLE 214 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 249 TABLE 215 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 249 TABLE 216 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 250 TABLE 217 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 250 TABLE 218 CHINA: MACROECONOMIC INDICATORS 251 TABLE 219 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 251 TABLE 220 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 252 TABLE 221 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 252 TABLE 222 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 252 TABLE 223 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 253 TABLE 224 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 253 TABLE 225 CHINA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 254 TABLE 226 CHINA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 254 TABLE 227 JAPAN: MACROECONOMIC INDICATORS 255 TABLE 228 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 256 TABLE 229 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 256 TABLE 230 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 256 TABLE 231 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 257 TABLE 232 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 257 TABLE 233 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 257 TABLE 234 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 258 TABLE 235 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 258 TABLE 236 INDIA: MACROECONOMIC INDICATORS 259 TABLE 237 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 260 TABLE 238 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 260 TABLE 239 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 260 TABLE 240 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 261 TABLE 241 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 261 TABLE 242 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 261 TABLE 243 INDIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 262 TABLE 244 INDIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 262 TABLE 245 AUSTRALIA: KEY MACROINDICATORS 263 TABLE 246 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 263 TABLE 247 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 264 TABLE 248 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 264 TABLE 249 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 264 TABLE 250 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 265 TABLE 251 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 265 TABLE 252 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 266 TABLE 253 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 266 TABLE 254 SOUTH KOREA: MACROECONOMIC INDICATORS 267 TABLE 255 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 267 TABLE 256 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 268 TABLE 257 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 268 TABLE 258 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 268 TABLE 259 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 269 TABLE 260 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 269 TABLE 261 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 270 TABLE 262 SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 270 TABLE 263 THAILAND: MACROECONOMIC INDICATORS 271 TABLE 264 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 271 TABLE 265 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 272 TABLE 266 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 272 TABLE 267 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 272 TABLE 268 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 273 TABLE 269 THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 273 TABLE 270 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 274 TABLE 271 THAILAND: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 274 TABLE 272 VIETNAM: MACROECONOMIC INDICATORS 275 TABLE 273 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 275 TABLE 274 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 276 TABLE 275 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 276 TABLE 276 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 276 TABLE 277 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 277 TABLE 278 VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 277 TABLE 279 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 278 TABLE 280 VIETAM: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 278 TABLE 281 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 279 TABLE 282 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 279 TABLE 283 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 280 TABLE 284 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 280 TABLE 285 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 280 TABLE 286 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 281 TABLE 287 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 281 TABLE 288 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 282 TABLE 289 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 283 TABLE 290 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 283 TABLE 291 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 284 TABLE 292 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 284 TABLE 293 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 284 TABLE 294 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 285 TABLE 295 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 285 TABLE 296 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 286 TABLE 297 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 286 TABLE 298 BRAZIL: MACROECONOMIC INDICATORS 287 TABLE 299 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 287 TABLE 300 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 288 TABLE 301 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 288 TABLE 302 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 288 TABLE 303 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 289 TABLE 304 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 289 TABLE 305 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 290 TABLE 306 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 290 TABLE 307 MEXICO: MACROECONOMIC INDICATORS 291 TABLE 308 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 291 TABLE 309 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 292 TABLE 310 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 292 TABLE 311 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 292 TABLE 312 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 293 TABLE 313 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 293 TABLE 314 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 294 TABLE 315 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 294 TABLE 316 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 295 TABLE 317 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 295 TABLE 318 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 295 TABLE 319 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 296 TABLE 320 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 296 TABLE 321 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 297 TABLE 322 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 297 TABLE 323 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 298 TABLE 324 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION) 299 TABLE 325 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 299 TABLE 326 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 300 TABLE 327 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 300 TABLE 328 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 300 TABLE 329 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 301 TABLE 330 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 301 TABLE 331 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 302 TABLE 332 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 302 TABLE 333 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 303 TABLE 334 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 303 TABLE 335 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 304 TABLE 336 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 304 TABLE 337 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 304 TABLE 338 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 305 TABLE 339 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 305 TABLE 340 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 306 TABLE 341 GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 306 TABLE 342 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 307 TABLE 343 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 307 TABLE 344 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 308 TABLE 345 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 308 TABLE 346 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 308 TABLE 347 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 309 TABLE 348 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 309 TABLE 349 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 310 TABLE 350 KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 310 TABLE 351 UNITED ARAB EMIRATES: KEY MACROINDICATORS 311 TABLE 352 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 311 TABLE 353 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 312 TABLE 354 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 312 TABLE 355 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 312 TABLE 356 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 313 TABLE 357 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 313 TABLE 358 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 314 TABLE 359 UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 314 TABLE 360 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 315 TABLE 361 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 315 TABLE 362 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 316 TABLE 363 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 316 TABLE 364 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 316 TABLE 365 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 317 TABLE 366 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 317 TABLE 367 OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 318 TABLE 368 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION) 319 TABLE 369 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 319 TABLE 370 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 320 TABLE 371 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION) 320 TABLE 372 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION) 320 TABLE 373 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION) 321 TABLE 374 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION) 321 TABLE 375 REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION) 322 TABLE 376 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET 324 TABLE 377 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION 327 TABLE 378 TOPICAL DRUG DELIVERY MARKET: REGION FOOTPRINT 332 TABLE 379 TOPICAL DRUG DELIVERY MARKET: PRODUCT TYPE FOOTPRINT 333 TABLE 380 TOPICAL DRUG DELIVERY MARKET: SITE OF APPLICATION FOOTPRINT 334 TABLE 381 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 337 TABLE 382 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 337 TABLE 383 TOPICAL DRUG DELIVERY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−JUNE 2025 340 TABLE 384 TOPICAL DRUG DELIVERY MARKET: DEALS, JANUARY 2022−JUNE 2025 341 TABLE 385 TOPICAL DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022–JUNE 2025 342 TABLE 386 TOPICAL DRUG DELIVERY MARKET: OTHERS, JANUARY 2022-JUNE 2025 344 TABLE 387 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 345 TABLE 388 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 346 TABLE 389 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS, JANUARY 2022−JUNE 2025 347 TABLE 390 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022−JUNE 2025 348 TABLE 391 GALDERMA: COMPANY OVERVIEW 349 TABLE 392 GALDERMA: PRODUCTS OFFERED 350 TABLE 393 GALDERMA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 351 TABLE 394 GALDERMA: DEALS, JANUARY 2022–JUNE 2025 352 TABLE 395 GALDERMA: EXPANSIONS, JANUARY 2022–JUNE 2025 352 TABLE 396 BAYER AG: COMPANY OVERVIEW 354 TABLE 397 BAYER AG: PRODUCTS OFFERED 355 TABLE 398 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 356 TABLE 399 BAYER AG: DEALS, JANUARY 2022–JUNE 2025 356 TABLE 400 NOVARTIS AG: COMPANY OVERVIEW 358 TABLE 401 NOVARTIS AG: PRODUCTS OFFERED 359 TABLE 402 NOVARTIS AG: DEALS, JANUARY 2022–JUNE 2025 360 TABLE 403 NOVARTIS AG: OTHERS, JANUARY 2022−JUNE 2025 360 TABLE 404 ABBVIE INC.: COMPANY OVERVIEW 362 TABLE 405 ABBVIE, INC.: PRODUCTS OFFERED 363 TABLE 406 ABBVIE INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025 364 TABLE 407 ABBVIE, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 365 TABLE 408 ABBVIE INC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 365 TABLE 409 GLENMARK PHARMACEUTICALS LIMITED: COMPANY OVERVIEW 367 TABLE 410 GLENMARK PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 368 TABLE 411 GLENMARK PHARMACEUTICALS LIMITED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 370 TABLE 412 GLENMARK PHARMACEUTICALS LIMITED: DEALS, JANUARY 2022–JUNE 2025 373 TABLE 413 GSK PLC.: COMPANY OVERVIEW 374 TABLE 414 GSK PLC.: PRODUCTS OFFERED 375 TABLE 415 GSK PLC.: DEALS, JANUARY 2022–JUNE 2025 376 TABLE 416 GSK PLC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 377 TABLE 417 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW 378 TABLE 418 BAUSCH HEALTH COMPANIES, INC.: PRODUCTS OFFERED 379 TABLE 419 BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 381 TABLE 420 BAUSCH HEALTH COMPANIES INC.: DEALS, JANUARY 2022–JUNE 2025 382 TABLE 421 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY OVERVIEW 383 TABLE 422 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCTS OFFERED 384 TABLE 423 HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022–JUNE 2025 385 TABLE 424 HISAMITSU PHARMACEUTICAL CO., INC.: DEALS, JANUARY 2022–JUNE 2025 386 TABLE 425 HISAMITSU PHARMACEUTICAL CO., INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 386 TABLE 426 CIPLA: COMPANY OVERVIEW 387 TABLE 427 CIPLA: PRODUCTS OFFERED 388 TABLE 428 CIPLA: DEALS, JANUARY 2022–JUNE 2025 391 TABLE 429 VIATRIS INC.: COMPANY OVERVIEW 392 TABLE 430 VIATRIS INC.: PRODUCTS OFFERED 393 TABLE 431 VIATRIS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 395 TABLE 432 VIATRIS INC.: DEALS, JANUARY 2022–JUNE 2025 396 TABLE 433 VIATRIS INC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 396 TABLE 434 ORGANON GROUP OF COMPANIES: COMPANY OVERVIEW 397 TABLE 435 ORGANON GROUP OF COMPANIES: PRODUCTS OFFERED 398 TABLE 436 ORGANON GROUP OF COMPANIES: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 399 TABLE 437 ORGANON GROUP OF COMPANIES: DEALS, JANUARY 2022–JUNE 2025 399 TABLE 438 PFIZER INC.: COMPANY OVERVIEW 400 TABLE 439 PFIZER INC.: PRODUCTS OFFERED 401 TABLE 440 PFIZER, INC.: PRODUCT APPROVALS, JANUARY 2022−JUNE 2025 402 TABLE 441 PFIZER, INC.: DEALS, JANUARY 2022−JUNE 2025 402 TABLE 442 CRESCITA THERAPEUTICS INC.: COMPANY OVERVIEW 403 TABLE 443 CRESCITA THERAPEUTICS INC.: PRODUCTS OFFERED 404 TABLE 444 CRESCITA THERAPEUTICS INC.: DEALS, JANUARY 2022–JUNE 2025 405 TABLE 445 CRESCITA THERAPEUTICS INC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025 405 TABLE 446 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 406 TABLE 447 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 407 TABLE 448 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022–JUNE 2025 408 TABLE 449 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022−APRIL 2025 408 TABLE 450 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 409 TABLE 451 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 410 TABLE 452 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022−JUNE 2025 411 TABLE 453 SOLVENTUM: COMPANY OVERVIEW 412 TABLE 454 SOLVENTUM: PRODUCTS OFFERED 413 TABLE 455 SOLVENTUM DEALS, JANUARY 2022–JUNE 2025 414 TABLE 456 LUYE PHARMA GROUP: COMPANY OVERVIEW 415 TABLE 457 LUYE PHARMA GROUP: PRODUCTS OFFERED 416 TABLE 458 LUYE PHARMA GROUP: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 417 TABLE 459 LUYE PHARMA GROUP: DEALS, JANUARY 2022−JUNE 2025 417 TABLE 460 LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW 418 TABLE 461 PURDUE PHARMA L.P.: COMPANY OVERVIEW 419 TABLE 462 PURDUE PHARMA L.P.: PRODUCTS OFFERED 419 TABLE 463 LAVIPHARM: COMPANY OVERVIEW 420 TABLE 464 LAVIPHARM: PRODUCTS OFFERED 421 TABLE 465 CMP PHARMA, INC.: COMPANY OVERVIEW 422 TABLE 466 ENCORE DERMATOLOGY, INC.: COMPANY OVERVIEW 423 TABLE 467 RUSAN PHARMA LTD.: COMPANY OVERVIEW 424 TABLE 468 ADHEXPHARMA: COMPANY OVERVIEW 425 FIGURE 1 TOPICAL DRUG DELIVERY MARKET & REGIONAL SEGMENTATION 37 FIGURE 2 TOPICAL DRUG DELIVERY MARKET: RESEARCH DESIGN 41 FIGURE 3 PRIMARY SOURCES 44 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS 46 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 46 FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 47 FIGURE 7 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS 48 FIGURE 8 TOPICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON 48 FIGURE 9 REVENUE ANALYSIS OF TOP FIVE COMPANIES: TOPICAL DRUG DELIVERY MARKET (2024) 49 FIGURE 10 PHARMACEUTICAL SALES APPROACH 50 FIGURE 11 TOP-DOWN APPROACH 50 FIGURE 12 BOTTOM-UP APPROACH 51 FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN TOPICAL DRUG DELIVERY MARKET (2025–2030): IMPACT ON MARKET GROWTH & CAGR) 53 FIGURE 14 CAGR PROJECTIONS 53 FIGURE 15 DATA TRIANGULATION METHODOLOGY 55 FIGURE 16 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION) 58 FIGURE 17 TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2025 VS. 2030 (USD BILLION) 59 FIGURE 18 TOPICAL DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION) 59 FIGURE 19 GEOGRAPHIC SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET 60 FIGURE 20 INCREASING PREVALENCE OF SKIN DISORDERS AND RISING INCIDENCE OF BURN INJURIES TO PROPEL MARKET 61 FIGURE 21 SEMI-SOLID FORMULATIONS SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 62 FIGURE 22 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 63 FIGURE 23 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63 FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 64 FIGURE 25 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 66 FIGURE 26 BIOPHARMACEUTICAL R&D SPENDING (2020–2026) 69 FIGURE 27 TOP PHARMA R&D INVESTMENTS: LEADING COMPANY INVESTMENTS, 2023 69 FIGURE 28 TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 81 FIGURE 29 TOPICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2014–JUNE 2025) 88 FIGURE 30 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2014–JUNE 2025) 89 FIGURE 31 AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024 93 FIGURE 32 AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024 93 FIGURE 33 AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024 94 FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS 99 FIGURE 35 KEY BUYING CRITERIA FOR TOPICAL DRUG DELIVERY PRODUCTS, BY TOP THREE END USERS 100 FIGURE 36 AI-USE CASES 103 FIGURE 37 TOPICAL DRUG DELIVERY MARKET: ECOSYSTEM MAP 105 FIGURE 38 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS 106 FIGURE 39 TOPICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO, 2020–2024 108 FIGURE 40 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 197 FIGURE 41 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 200 FIGURE 42 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT 246 FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2022–2024 326 FIGURE 44 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2024 327 FIGURE 45 RANKING OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2024 329 FIGURE 46 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 330 FIGURE 47 TOPICAL DRUG DELIVERY MARKET: COMPANY FOOTPRINT 331 FIGURE 48 TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 336 FIGURE 49 TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 338 FIGURE 50 R&D EXPENDITURE OF KEY PLAYERS, 2022–2024 339 FIGURE 51 EV/EBITDA OF KEY VENDORS 339 FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 340 FIGURE 53 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024) 346 FIGURE 54 GALDERMA: COMPANY SNAPSHOT (2024) 350 FIGURE 55 BAYER AG: COMPANY SNAPSHOT (2024) 355 FIGURE 56 NOVARTIS AG: COMPANY SNAPSHOT (2024) 359 FIGURE 57 ABBVIE, INC.: COMPANY SNAPSHOT (2024) 362 FIGURE 58 GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024) 367 FIGURE 59 GSK PLC.: COMPANY SNAPSHOT (2024) 375 FIGURE 60 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024) 379 FIGURE 61 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2024) 383 FIGURE 62 CIPLA: COMPANY SNAPSHOT (2024) 388 FIGURE 63 VIATRIS INC.: COMPANY SNAPSHOT (2024) 393 FIGURE 64 ORGANON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024) 398 FIGURE 65 PFIZER, INC.: COMPANY SNAPSHOT (2024) 401 FIGURE 66 CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2024) 404 FIGURE 67 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024) 407 FIGURE 68 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024) 409 FIGURE 69 SOLVENTUM: COMPANY SNAPSHOT (2024) 413 FIGURE 70 LUYE PHARMA GROUP: COMPANY SNAPSHOT (2023) 416 FIGURE 71 COMPANY SNAPSHOT: LAVIPHARM (2024) 420